Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reserv...oir of the infections. There is a strong need to control AAT, as is claimed by the European Commission in a recent document on the reservation of antimicrobials for human use. Control of AAT is considered part of the One Health approach established by the FAO program against African Trypanosomiasis. Under the umbrella of the One Health concepts, in this work, by analyzing the pharmacological properties of the therapeutic options against Trypanosoma brucei spp., we underline the need for clearer and more defined guidelines in the employment of drugs designed for HAT and AAT. Essential requirements are addressed to meet the challenge of drug use and drug resistance development. This approach shall avoid inter-species cross-resistance phenomena and retain drugs therapeutic activity.
more
In South and Central America, lymphatic filariasis (LF) is caused by Wuchereria bancrofti, which is transmitted by Culex quinquefasciatus, the only vector species in this region. Of the seven countries considered endemic for LF in the Americas in the last decade, Costa Rica, Suriname and Trinidad a...nd Tobago were removed from the World Health Organization list in 2011. The remaining countries, Brazil, Dominican Republic, Guyana and Haiti, have achieved important progress in recent years. Brazil was the first country in the Americas to stop mass drug administration (MDA) and to establish post-MDA surveillance. Dominican Republic stopped MDA in all LF-endemic foci: La Ciénaga and Southwest passed the third Transmission Assessment Survey (TAS) and the Eastern focus passed TAS-1 in 2018. Haiti passed the TAS and interrupted transmission in >80% of endemic communes, achieving effective drug coverage. Guyana implemented effective coverage in MDAs in 2017 and 2018 and in 2019 scaled up the treatment for 100% of the geographical region, introducing ivermectin in the MDA in order to achieve LF elimination by the year 2026. The Americas region is on its way to eliminating LF transmission. However, efforts should be made to improve morbidity management to prevent disability of the already affected populations.
more
The main objective of the health systems is to meet the health needs of the population in general, but for this the system must have adequate financing and supply support to cover the entire population in question and check quality, efficiency, equity services, safety and sustainability. However, co...nsidering the segmented Peruvian health system, this makes it more deficient in comprehensive care for the population due to the duplication of functions, misuse of its resources, absence of complementary services. Due to the COVID-19 pandemic, this deficiency in the Peruvian health system became more evident owing to the high number of
deaths and its state of collapse, combining these factors this scope review aims to map the current state of the Peruvian health system, its structure, synthesize data on the performance of the health system (in terms of access, coverage and quality of health services) and identify the main public health policies available
more
Front. Vet. Sci., 01 December 2021
The climate crisis has many consequences – among them widespread health impacts that will lead to immense societal, ecological, and economic harm.
Over the past two decades multiple large-scale reviews on climate change and health have made clear the need for a multi-sectoral approach to target t...he drivers and impacts of climate change, biodiversity loss, and ecosystem degradation. Despite this abundance of scientific evidence underscoring urgency of action, policy implementation responses lag behind. Even at COP26, itself delayed due to an ongoing pandemic, health continues to be considered by many countries a problem independent from climate and environment.
more
Временные методические рекомендации
Версия 1 (14.08.2020)
La tuberculosis persiste como una grave problemática para la salud pública a nivel internacional y nacional dado que continúa siendo una de las diez primeras causas de morbilidad y mortalidad derivada de enfermedades infectocontagiosas en la población.
Science 31 Jan 2020: Vol. 367, Issue 6477, pp. 569-573
DOI: 10.1126/science.aay8833
PLOS ONE | https://doi.org/10.1371/journal.pone.0217693 June 7, 2019
Editorial Review
AIDS 2019, 33:1411–1420
Southern African Journal of HIV Medicine
ISSN: (Online) 2078-6751, (Print) 1608-9693
http://www.sajhivmed.org.za
Published: 23 May 2018
International Journal of Infectious Diseases 70 (2018) 121–130
https://doi.org/10.1016/j.ijid.2018.03.007
1201-9712/© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://cr...eativecommons.org/licenses/by-nc-nd/4.0/).
more
Journal of Virus Eradication 2018; 4 (Supplement 2): 33–39
Includes a Special Report on the Financial and Personal Benefits of Early Diagnosis
2018 Alzheimer’s Disease Facts and Figures is a statistical resource for U.S. data related to Alzheimer’s disease,
the most common cause of dementia. Background and context for interpretating the data are con...tained in
the Overview. Additional sections address prevalence, mortality and morbidity, caregiving and use and costs of health care and services. A Special Report discusses the financial and personal benefits of diagnosing earlier in the disease process, in the stage of mild cognitive impairment.
more
Clinical Medicine
JCI Insight. 2017;2(7):e91963.
The European Journal of Public Health, Vol. 28, No. 1, 145–149
The Author 2017. Published by Oxford University Press on behalf of the European Public Health Association.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:...//creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
doi:10.1093/eurpub/ckx122 Advance Access published on 31 August 2017
more
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
New England Journal of Medicine 374:1,pp23-32